Literature DB >> 21499229

Geographic variation in the prevalence of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly: a comparative analysis of a Mexican and a German population.

Annegret Hofscheier1, Ana Ponciano, Irina Bonzheim, Patrick Adam, Carmen Lome-Maldonado, Teresa Vela, Evelyn Cortes, Carlos Ortiz-Hidalgo, Falko Fend, Leticia Quintanilla-Martinez.   

Abstract

Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma of the elderly was included as a provisional entity in the 2008 WHO lymphoma classification. Most reports of this disease come from Asia and little is known about it in other regions of the world, including Latin America. Therefore, in this study, 305 diffuse large B-cell lymphomas in patients above 50 years were analyzed, 136 from Mexico and 169 from Germany. EBV was detected by Epstein-Barr early RNA (EBER) in situ hybridization. Only cases with EBER+ in the majority of tumor cells were regarded as EBV+ diffuse large B-cell lymphoma. The prevalence of EBV+ diffuse large B-cell lymphoma in Mexican patients was found to be 7% (9 of 136), whereas only 2% (4 of 169) of the German cases were positive. The median age at diagnosis was 66 years in the Mexican cohort, as opposed to 77 years in the German group. The site of presentation was in both groups predominantly nodal in nine cases (70%) and extranodal in four cases (30%). Of the 13 EBV+ cases, 10 (77%) were classified as polymorphic and 3 (23%) as monomorphic type. The polymorphic cases showed a non-germinal center B-cell immunophenotype (CD10- MUM1+). Twelve cases (92%) were LMP1 positive and two (15%) expressed EBNA2. An interesting finding was the high frequency of EBV type B with the LMP1 30 bp deletion found in the Mexican cases (50%). Eight of the 11 evaluable cases were B-cell monoclonal by polymerase chain reaction. In summary, we found a similar prevalence of EBV+ diffuse large B-cell lymphoma of the elderly in a Mexican population compared with what has been reported in Asian countries, and in contrast to the low frequency in Western populations (1-3%). However, compared with the Asian series, the Mexican patients were younger at diagnosis, presented predominantly with nodal disease and rarely expressed EBNA2 protein.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21499229     DOI: 10.1038/modpathol.2011.62

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  34 in total

Review 1.  Epstein-Barr Virus-associated lymphoproliferative disorders: experimental and clinical developments.

Authors:  Lingyun Geng; Xin Wang
Journal:  Int J Clin Exp Med       Date:  2015-09-15

2.  The proportion of activated B-cell like subtype among de novo diffuse large B-cell lymphoma increases with age.

Authors:  Sylvain Mareschal; Hélène Lanic; Philippe Ruminy; Christian Bastard; Hervé Tilly; Fabrice Jardin
Journal:  Haematologica       Date:  2011-08-22       Impact factor: 9.941

3.  Different prevalence and clinical outcome of Epstein-Barr virus positive diffuse large B-cell lymphoma between North American and non-Western populations.

Authors:  Lihui Yin; Zijun Y Xu-Monette; Jay Brock; Yong Li; Ken H Young
Journal:  Ann Transl Med       Date:  2018-06

Review 4.  [Epstein-Barr virus-associated lymphoproliferations and lymphomas].

Authors:  I Anagnostopoulos; K Jöhrens
Journal:  Pathologe       Date:  2013-05       Impact factor: 1.011

5.  EBV-positive large B-cell lymphomas in young patients: a nodal lymphoma with evidence for a tolerogenic immune environment.

Authors:  Alina Nicolae; Stefania Pittaluga; Shahed Abdullah; Seth M Steinberg; Thu Anh Pham; Theresa Davies-Hill; Liqiang Xi; Mark Raffeld; Elaine S Jaffe
Journal:  Blood       Date:  2015-05-21       Impact factor: 22.113

6.  Clinicopathological features of adult T-cell leukemia/lymphoma with HTLV-1-infected Hodgkin and Reed-Sternberg-like cells.

Authors:  Kennosuke Karube; Mitsuyoshi Takatori; Shugo Sakihama; Yuma Tsuruta; Takashi Miyagi; Kazuho Morichika; Sakiko Kitamura; Norihiro Nakada; Masaki Hayashi; Shohei Tomori; Iwao Nakazato; Kazuiku Ohshiro; Naoki Imaizumi; Yara Yukie Kikuti; Naoya Nakamura; Satoko Morishima; Hiroaki Masuzaki; Takuya Fukushima
Journal:  Blood Adv       Date:  2021-01-12

7.  Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries.

Authors:  Chi Young Ok; Ling Li; Zijun Y Xu-Monette; Carlo Visco; Alexander Tzankov; Ganiraju C Manyam; Santiago Montes-Moreno; Karen Dybkaer; Karen Dybaer; April Chiu; Attilio Orazi; Youli Zu; Govind Bhagat; Jiayu Chen; Kristy L Richards; Eric D Hsi; William W L Choi; J Han van Krieken; Jooryung Huh; Weiyun Ai; Maurilio Ponzoni; Andrés J M Ferreri; John P Farnen; Michael B Møller; Carlo E Bueso-Ramos; Roberto N Miranda; Jane N Winter; Miguel A Piris; L Jeffrey Medeiros; Ken H Young
Journal:  Clin Cancer Res       Date:  2014-02-28       Impact factor: 12.531

Review 8.  Aggressive B-cell lymphomas: how many categories do we need?

Authors:  Jonathan W Said
Journal:  Mod Pathol       Date:  2012-11-16       Impact factor: 7.842

9.  Primary CNS lymphoma in scleroderma: a case series.

Authors:  Danielle M Robinett; Laura K Hummers; Meaghan Morris; Amy S Duffield; Ami A Shah
Journal:  J Scleroderma Relat Disord       Date:  2020-11-11

10.  CD5 positivity is an independent adverse prognostic factor in elderly patients with diffuse large B cell lymphoma.

Authors:  Wen-Yu Chuang; Hung Chang; Lee-Yung Shih; Po-Nan Wang; Yu-Sun Chang; Tung-Liang Lin; Yu-Shin Hung; Chi-Ju Yeh; Shir-Hwa Ueng; Tzung-Chih Tang; Ming-Chung Kuo; Po Dunn; Jin-Hou Wu; Hsiao-Wen Kao; Che-Wei Ou; Yung-Liang Wan; Chuen Hsueh
Journal:  Virchows Arch       Date:  2015-09-14       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.